MarketCap
Alnylam Pharmaceuticals ALNY
$ 227.75
0.59%
Facebook
X
Telegram
Alnylam Pharmaceuticals Revenue | ALNY
Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.
Traditionally defined as follows:Revenue = Price * Quantity of productsRevenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]
This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.
Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.
Annual Revenue Alnylam Pharmaceuticals
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 3.71 B | 2.25 B | 1.83 B | 1.04 B | 844 M | 493 M | 220 M | 74.9 M | 89.9 M | 47.2 M | 41.1 M | 50.6 M | 47.2 M | 66.7 M | 82.8 M | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 3.71 B | 41.1 M | 726 M |
Quarterly Revenue Alnylam Pharmaceuticals
| 2026-Q2 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | 2010-Q3 | 2010-Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.29 B | 1.25 B | 774 M | 594 M | - | 501 M | 660 M | 494 M | - | 751 M | 319 M | 319 M | - | 264 M | 225 M | 213 M | - | 188 M | 221 M | 178 M | 164 M | 126 M | 104 M | 99.5 M | 71.7 M | 70.1 M | 44.7 M | 33.3 M | 21 M | 2.07 M | 29.9 M | 21.9 M | 37.9 M | 17.1 M | 15.9 M | 19 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -1.61 M | -1.14 M | -889 K | - | -467 K | -1.01 M | 20.9 M | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 1.29 B | -1.61 M | 240 M |
References
- Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).
Revenue of other stocks in the Biotechnology industry
| Issuer | Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Vericel Corporation
VCEL
|
276 M | $ 43.8 | 2.97 % | $ 2.2 B |  USA |
 |
Veracyte
VCYT
|
517 M | $ 48.15 | 0.45 % | $ 3.78 B | USA |
 |
Vir Biotechnology
VIR
|
68.6 M | $ 10.95 | 3.6 % | $ 1.52 B | USA |
 |
Nanobiotix S.A.
NBTX
|
32.6 M | $ 31.55 | 7.32 % | $ 1.51 T |  France |
 |
Viking Therapeutics
VKTX
|
10.7 K | $ 24.27 | -0.53 % | $ 2.73 B | USA |
 |
PainReform Ltd.
PRFX
|
17 K | $ 0.73 | -2.01 % | $ 473 K |  Israel |
 |
Vanda Pharmaceuticals
VNDA
|
216 M | $ 3.97 | -1.12 % | $ 234 M | USA |
 |
PTC Therapeutics
PTCT
|
1.73 B | $ 60.55 | -0.07 % | $ 4.82 B | USA |
 |
Protagonist Therapeutics
PTGX
|
46 M | $ 140.74 | 1.68 % | $ 8.95 B | USA |
 |
Verrica Pharmaceuticals
VRCA
|
35.6 M | $ 3.64 | 3.08 % | $ 38.8 M | USA |
 |
Viridian Therapeutics
VRDN
|
70.8 M | $ 22.88 | 2.26 % | $ 2.33 B | USA |
 |
Arcus Biosciences
RCUS
|
247 M | $ 17.97 | -2.97 % | $ 1.93 B | USA |
 |
Seer
SEER
|
16.6 M | $ 1.94 | -1.52 % | $ 107 M | USA |
 |
Verastem
VSTM
|
30.9 M | $ 10.05 | 0.05 % | $ 697 M | USA |
 |
VistaGen Therapeutics
VTGN
|
1.27 M | $ 0.17 | -5.29 % | $ 6.47 M | USA |
 |
vTv Therapeutics
VTVT
|
1.02 M | $ 25.91 | 1.39 % | $ 102 M | USA |
 |
Voyager Therapeutics
VYGR
|
40.4 M | $ 1.74 | -1.15 % | $ 102 M | USA |
 |
REGENXBIO
RGNX
|
170 M | $ 6.6 | -1.2 % | $ 340 M | USA |
 |
Nuvation Bio
NUVB
|
62.9 M | $ 4.56 | -0.22 % | $ 1.56 B | USA |
 |
Rigel Pharmaceuticals
RIGL
|
294 M | $ 49.63 | 3.12 % | $ 893 M | USA |
 |
Processa Pharmaceuticals
PCSA
|
5 K | $ 1.81 | -2.76 % | $ 2.37 M | USA |
 |
RedHill Biopharma Ltd.
RDHL
|
8.04 M | $ 0.42 | -0.52 % | $ 5.18 B | Israel |
 |
Wave Life Sciences Ltd.
WVE
|
42.7 M | $ 3.18 | -0.16 % | $ 536 M |  Singapore |
 |
Xenetic Biosciences
XBIO
|
2.98 M | $ 1.83 | 6.4 % | $ 3.11 M | USA |
|
XBiotech
XBIT
|
4.01 M | $ 1.85 | -4.15 % | $ 56.4 M | USA |
 |
Xenon Pharmaceuticals
XENE
|
7.5 M | $ 35.44 | 0.28 % | $ 2.81 B |  Canada |
 |
Xeris Pharmaceuticals
XERS
|
292 M | $ 10.34 | 1.37 % | $ 1.66 B | USA |
 |
X4 Pharmaceuticals
XFOR
|
6.5 M | $ 3.25 | 0.15 % | $ 137 M | USA |
 |
XTL Biopharmaceuticals Ltd.
XTLB
|
451 K | $ 2.02 | 2.54 % | $ 1.36 B | Israel |
 |
22nd Century Group
XXII
|
17.6 M | $ 0.09 | -53.06 % | $ 16.6 K | USA |
|
Silence Therapeutics plc
SLN
|
5.3 M | $ 19.72 | 0.25 % | $ 2.79 B |  Britain |
 |
Zai Lab Limited
ZLAB
|
460 M | $ 24.15 | 0.5 % | $ 26.5 B |  China |
 |
Zentalis Pharmaceuticals
ZNTL
|
67.4 M | $ 2.13 | -3.85 % | $ 153 M | USA |
 |
Revolution Medicines
RVMD
|
11.6 M | $ 184.88 | -1.13 % | $ 35.2 B | USA |
 |
Zoetis
ZTS
|
9.47 B | $ 80.41 | -0.77 % | $ 35.7 B | USA |
 |
Zymeworks
ZYME
|
26.7 M | $ 27.87 | -1.24 % | $ 1.44 B | Canada |
 |
Akari Therapeutics, Plc
AKTX
|
368 K | $ 8.35 | 1.52 % | $ 562 B | Britain |
 |
Alector
ALEC
|
21 M | $ 1.89 | 3.28 % | $ 195 M | USA |
 |
Aligos Therapeutics
ALGS
|
2.19 M | $ 4.59 | -3.97 % | $ 45.4 M | USA |
 |
Alkermes plc
ALKS
|
1.48 B | $ 44.29 | 1.51 % | $ 7.29 B |  Irlanda |
 |
Allogene Therapeutics
ALLO
|
22 K | $ 1.23 | -1.5 % | $ 271 M | USA |
 |
Cleveland BioLabs, Inc.
CBLI
|
263 K | - | -7.31 % | $ 49 M | USA |
 |
Amgen
AMGN
|
36.8 B | $ 440.91 | 0.37 % | $ 237 B | USA |
 |
Amarin Corporation plc
AMRN
|
214 M | $ 12.08 | 2.46 % | $ 5.01 B | Irlanda |
 |
Amneal Pharmaceuticals
AMRX
|
3.02 B | $ 21.09 | 3.46 % | $ 6.61 B | USA |
 |
AnaptysBio
ANAB
|
53 M | $ 48.68 | -0.1 % | $ 1.41 B | USA |
 |
Aclaris Therapeutics
ACRS
|
7.83 M | $ 3.82 | 1.73 % | $ 468 M | USA |
 |
AC Immune SA
ACIU
|
3.57 M | $ 2.33 | -3.93 % | $ 235 M |  Schweiz |